Ganirelix
Ganirelix is an FDA-approved GnRH receptor antagonist. Ganirelix is a GnRH decapeptide analog with substitutions at positions 1, 2, 3, 6, 8 and 10 that confer competitive antagonism at the pituitary GnRH receptor. Binding induces rapid, reversible suppression of gonadotropin secretion, with luteinising hormone falling more than follicle-stimulating hormone.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 1570.3 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Synthetic decapeptide GnRH receptor antagonist approved to prevent premature luteinising hormone surges in women undergoing controlled ovarian hyperstimulation.
Peptide Library's Ganirelix profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Ganirelix is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C80H113ClN18O13 |
|---|---|
| Molecular weight | 1570.3 g/mol |
| PubChem CID | 16130957 |
| FDA UNII | IX503L9WN0 |
| ChEMBL | CHEMBL1251 |
| DrugBank | DB06785 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Ganirelix is a GnRH decapeptide analog with substitutions at positions 1, 2, 3, 6, 8 and 10 that confer competitive antagonism at the pituitary GnRH receptor. Binding induces rapid, reversible suppression of gonadotropin secretion, with luteinising hormone falling more than follicle-stimulating hormone. Its effect is dose-dependent and gonadotropin secretion recovers promptly after the last dose.
Studies
- Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study
- GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy
- The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI
- Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon)
- The effects of GnRH antagonist on the endometrium of normally menstruating women
Regulatory & research status
Ganirelix is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Ganirelix: frequently asked questions
What is Ganirelix?
Synthetic decapeptide GnRH receptor antagonist approved to prevent premature luteinising hormone surges in women undergoing controlled ovarian hyperstimulation.
How does Ganirelix work?
Ganirelix is a GnRH decapeptide analog with substitutions at positions 1, 2, 3, 6, 8 and 10 that confer competitive antagonism at the pituitary GnRH receptor. Binding induces rapid, reversible suppression of gonadotropin secretion, with luteinising hormone falling more than follicle-stimulating hormone.
Is Ganirelix FDA approved?
Yes. Ganirelix is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Ganirelix?
Compounds most often compared with Ganirelix include Degarelix, Cetrorelix, Leuprolide and Gonadorelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study — J Obstet Gynaecol, 2022External reference
- GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy — Pharmaceuticals (Basel), 2024External reference
- The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI — Hum Reprod, 2004External reference
- Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon) — Fertil Steril, 2001External reference
- The effects of GnRH antagonist on the endometrium of normally menstruating women — J Assist Reprod Genet, 2007External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Ganirelix profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Ganirelix research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →